As of Mar 24
| +0.24 / +2.60%|
The 8 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 13.00, with a high estimate of 15.00 and a low estimate of 8.00. The median estimate represents a +37.42% increase from the last price of 9.46.
The current consensus among 9 polled investment analysts is to Buy stock in Array Biopharma Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.